# Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

> **NCT00657709** · PHASE3 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 3630 (actual)

## Conditions studied

- Serogroup B Meningococcal Meningitis

## Interventions

- **BIOLOGICAL:** Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1)
- **BIOLOGICAL:** Serogroup B meningococcal Vaccine lot 2 (rMenB Lot 2)
- **BIOLOGICAL:** Serogroup B meningococcal Vaccine lot 3 (rMenB Lot 3)
- **BIOLOGICAL:** Infanrix Hexa
- **BIOLOGICAL:** Menjugate
- **BIOLOGICAL:** Prevenar

## Key facts

- **NCT ID:** NCT00657709
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 3630 (ACTUAL)
- **Last updated:** 2017-10-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00657709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00657709, "Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00657709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*